Bristol Myers Squibb Company has been in Cobenfy (xanomeline and trospium chloride) launch mode for several months in anticipation of the US Food and Drug Administration’s approval decision of the M1/M4 muscarinic agonist as a treatment for adults with schizophrenia, which the agency granted as scheduled on 26 September. BMS plans to make the drug – formerly known as KarXT, which it acquired in the $14bn purchase of Karuna Therapeutics, Inc. – available within the next month.
BMS To Launch Novel Schizophrenia Therapy Cobenfy Within The Next Month
KarXT Came From $14bn Karuna Buy
BMS said Cobenfy’s annual list price of $22,500 is in line with other branded antipsychotics and sees the drug as a 2025 launch given late 2024 approval and ongoing reimbursement talks.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
More from Leadership
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.